Latest Boehringer Ingelheim Stories
ST. JOSEPH, Mo., April 25, 2012 /PRNewswire/ -- On Wednesday, April 25, veterinarians are going to the dogs in Pittsburgh. Veterinary cardiologists on the Mobile Dog Heart Health Tour will stop with a soundproof medical unit to perform free dog heart examinations at Hartwood Acres. (Photo: https://photos.prnewswire.com/prn/20100603/CG14051 ) In addition to providing free heart health screenings, veterinarians will be available to answer questions for dog owners about heart...
INDIANAPOLIS, April 25, 2012 /PRNewswire/ -- Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in other products and key regions. Cymbalta revenue increased 23 percent due to strong growth in both the U.S. and international markets, while Effient revenue more than doubled. Elanco Animal Health revenue grew 33 percent, driven by gains in both the food animal and companion animal...
PLEASANTON, California, April 25, 2012 /PRNewswire/ -- Boehringer Ingelheim, a Top 20 global pharmaceutical company has selected Veeva CRM, including iRep for the iPad, for global deployment supporting its prescription medicine commercial and medical teams. Boehringer Ingelheim is headquartered in Germany, and operates globally with 145 affiliates and more than 42,000 employees. Over 13,500 users in 60 markets worldwide will go live on Veeva's cloud-based solution over the...
MONROVIA, Calif., April 4, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim. The payment was triggered by a regulatory submission to begin Phase 1 clinical trials of a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the second XmAb candidate entering human clinical trials under the agreement with Boehringer...
ATLANTA, March 9, 2012 /PRNewswire/ -- Inhibikase Therapeutics, Inc. today announced the election of Dr. Peter Mueller of Vertex Pharmaceuticals to the Board of Directors of Inhibikase Therapeutics, Inc. (LOGO: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO) Dr. Mueller joined Vertex Pharmaceuticals in 2003 and currently serves as the Executive Vice President, Global Research & Development and Chief Scientific Officer. Dr. Mueller is also driving corporate development...
RIDGEFIELD, Conn. and INDIANAPOLIS, March 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto(TM) (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S. JENTADUETO is a new prescription medication for patients who need to control their blood sugar. Taken twice daily, it combines two diabetes medicines - the...
RIDGEFIELD, Conn., March 1, 2012 /PRNewswire/ -- Every year, colon cancer takes the lives of tens of thousands of mothers, fathers, husbands, wives and friends, despite the fact that with an early screening, these deaths are highly preventable. This March during National Colorectal Cancer Awareness Month, the Colon Cancer Alliance (CCA) and makers of Dulcolax® are urging people to make an appointment with their doctor and schedule a colon cancer screening. "While the idea of...
MONROVIA, Calif. and INGELHEIM, Germany, Feb. 21, 2012 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies. Under the terms of the agreement, Boehringer Ingelheim will provide all manufacturing and product supply from preclinical through Phase 1 development....
BEDFORD, Ohio, Feb. 16, 2012 /PRNewswire/ -- Bedford Laboratories(TM) announces a nationwide voluntary recall for the following three lots of Cytarabine for Injection, USP: Cytarabine for Injection, USP 1 gram per vial - NDC #55390-133-01 Lot 2066986 - Exp. Date March 31, 2014 Lot 2111675 - Exp. Date December 31, 2013 Lot 2131148 - Exp. Date May 31, 2014 (Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO ) This voluntary market recall is being conducted due to a...
RIDGEFIELD, Conn., Feb. 3, 2012 /PRNewswire/ -- Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. These data were presented at the International Stroke Conference (ISC) in New Orleans. "Omeprazole has been shown to interact with...
